GE Vernova Inc vs GeneDx Holdings Corp — how do they compare? GE Vernova Inc trades at $1,034.68 (market cap $283.57B), while GeneDx Holdings Corp trades at $61.39 (market cap $1.96B). The key difference: GE Vernova Inc is far larger — about 144.7× GeneDx Holdings Corp's market cap, and GE Vernova Inc pays a 0.19% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| GEV | WGS | |
|---|---|---|
Market Cap | $283.57B | $1.96B |
Sector | Technology | Technology |
52-Week High | $1.17K | $167.51 |
52-Week Low | $547.96 | $34.51 |
Enterprise Value | $276.21B | $1.96B |
Dividend Yield | 0.19% | — |
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) stock trades at $1,021.20, down 4.2% over 24 hours, as it approaches its Q2 2026 earnings report on July 22. The technical picture is mixed, with a bearish overall signal but a bullish moving average crossover. Fundamentally, the company shows strong profitability with a 23.81% net margin and robust ROE of 83.23%, though valuation ratios like a P/E of 30.84 and EV/EBITDA of 109.82 appear elevated. Recent earnings have been volatile, with a significant beat in Q1 2026 but a miss in Q3 2025. Analyst sentiment remains overwhelmingly positive, with a 75% buy rating and a consensus price target of $1,260, representing over 23% upside. The company is positioned to benefit from AI-driven power demand and grid modernization, highlighted by recent news coverage and an $11 billion investment push.
The outlook for GEV is cautiously optimistic, driven by its leadership in power infrastructure and exposure to secular growth in AI and data center energy demand. Key opportunities include pricing power from scarce gas turbines, a massive global installed base, and growth in its nuclear segment with the BWRX-300 Small Modular Reactor. Primary risks include execution challenges in its Wind segment, high valuation multiples that leave little room for error, and potential volatility around earnings. The stock's recent decline may present a buying opportunity ahead of earnings for investors bullish on the long-term AI power theme.
WGS trades at $62.73, up 0.48% on the day, amid a bearish technical signal and negative earnings momentum. The stock faces significant headwinds from a class action lawsuit alleging securities fraud tied to a 49% stock decline, while fundamentals show a net loss of $21.02 million in 2025 and deteriorating profitability into 2026. Analyst consensus remains bullish with a $75.40 price target, but recent news flow is overwhelmingly negative.
The outlook is clouded by legal risks and weak financial performance, though analyst optimism suggests potential recovery if the company can stabilize operations. Key risks include litigation outcomes, execution on profitability, and market sentiment shifts. The stock's trajectory hinges on resolving legal challenges and demonstrating sustainable earnings improvement.
Trailing returns across standard periods
Latest headlines on both assets
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →